浏览全部资源
扫码关注微信
山东中医药大学第二附属医院药学部,济南 250001
Published:30 June 2023,
Received:29 November 2022,
Revised:15 May 2023,
扫 描 看 全 文
鹿岩,化晓凯,张红艳等.经典名方参苓白术散的古今文献考证及研究热点分析 Δ[J].中国药房,2023,34(12):1449-1455.
LU Yan,HUA Xiaokai,ZHANG Hongyan,et al.Textual research on ancient and modern literature and analysis on research hot spots of classical prescription Shenling baizhu powder[J].ZHONGGUO YAOFANG,2023,34(12):1449-1455.
鹿岩,化晓凯,张红艳等.经典名方参苓白术散的古今文献考证及研究热点分析 Δ[J].中国药房,2023,34(12):1449-1455. DOI: 10.6039/j.issn.1001-0408.2023.12.08.
LU Yan,HUA Xiaokai,ZHANG Hongyan,et al.Textual research on ancient and modern literature and analysis on research hot spots of classical prescription Shenling baizhu powder[J].ZHONGGUO YAOFANG,2023,34(12):1449-1455. DOI: 10.6039/j.issn.1001-0408.2023.12.08.
目的
2
为参苓白术散的临床应用和进一步研究开发提供借鉴。
方法
2
利用文献考证和计量学方法对古代和近代医籍中参苓白术散的组成、剂量、炮制、用法等关键信息进行系统的归纳整理,并对现代文献的发文量、关键词等内容进行可视化分析。结果与
结论
2
参苓白术散最早收载于《太平惠民和剂局方》(以下简称“局方”),历代核心药物组成、应用最多的剂量比例均与局方相同;基本以制末、调服为主;用量集中于2~3钱;功能主治和应用范围较局方有一定拓展,临床应用也从内科逐渐延伸到外科、妇科、儿科、眼科、皮肤科等,总体上覆盖了脾虚所致病症的各个方面;组方原理围绕“健脾、益气、除湿”;组方药物建议都选用药典中的相应饮片品种。现代研究主要围绕临床展开,以中医或中西医结合该方加减治疗各类肠病、腹泻病、肺病为主,研究重点是疗效、应用,且已开始探讨其作用机制。该方在文献中的用法与药典收录有不一致之处,有待进一步研究。
OBJECTIVE
2
To provide reference for the clinical application and further research and development of Shenling baizhu powder.
METHODS
2
Using the methods of textual research and bibliometrics, the key information such as the composition, dose, processing and usage of Shenling baizhu powder in ancient and modern literature were systematically summarized and sorted out, and the number of publications, keywords, and other contents of modern literature were visually analyzed.
RESULTS &
CONCLUSIONS
2
Shenling baizhu powder was first collected in
Taiping Huimin Hejiju Fang
(abbreviated “Jufang”), the composition of core drugs and most widely used dose ratio in previous generations were the same as those in Jufang, basically focusing on powder making and being taken after mixed with liquid; the dosage was concentrated on 2-3 qian; the function and application of it had been expanded to a certain extent compared with Jufang; its clinical application had gradually extended from internal medicine to surgery, gynecology, pediatrics, ophthalmology, dermatology, etc., covering all aspects of the disease caused by spleen deficiency in general; the composition mechanism revolved around “strengthening the spleen, replenishing qi and removing dampness”; the recommended prescription drugs were all selected from the corresponding varieties in the pharmacopoeia. Modern research mainly focuses on clinical practice, with traditional Chinese medicine or traditional Chinese and Western medicine combined with this formula as the main modified treatment for various intestinal diseases, diarrhea diseases, and lung diseases. The efficacy and application are the frontier hot spots today, and the mechanism of action has begun to be explored. The usage in the literature and the inclusion in the pharmacopoeia are inconsistent, and further research is needed.
参苓白术散健脾益气除湿医籍医方溃疡性结肠炎文献考证
strengthening the spleenreplenishing qiremoving dampnessmedical registration and prescriptionulcerative colitistextual research
太平惠民和剂局.太平惠民和剂局方[M].刘景源,点校.北京:人民卫生出版社,1985:109.
刘惠杰,何军.参苓白术散[M].北京:中国医药科技出版社,2009:3.
国家药典委员会.中华人民共和国药典:一部[S].2020年版.北京:中国医药科技出版社,2020:4-402.
钱乙.小儿药证直诀[M].郭君双,整理.北京:人民卫生出版社,2006:46.
虞抟.医学正传[M].北京:人民卫生出版社,1965:70.
王銮.幼科类萃[M].北京:中医古籍出版社,2015:111.
龚信.古今医鉴[M].达美君,王荣根,周金根,等校注.北京:中国中医药出版社,2007:95-96.
吴昆,北山友松绳愆.医方考绳愆:下册[M].北京:中国科学技术出版社,1996:3.
国家药典委员会.中华人民共和国药典临床用药须知:中药饮片卷[S].2015年版.北京:中国医药科技出版社,2017:1110.
丘光明,邱隆,杨平.中国科学技术史:度量衡卷[M].北京:科学出版社,2001:447.
郑金生.海外回归中医善本古籍丛书:第七册[M].北京:人民卫生出版社,2003:309.
徐春甫.医学指南捷径六书[M].张志斌,校注.北京:中国中医药出版社,2015:216-217.
吴昆.医方考[M].洪青山,校注.北京:中国中医药出版社,1998:162.
李中梓.删补颐生微论[M].包来发,郑贤国,校注.北京:中国中医药出版社,1998:245.
汪昂.医方集解[M].苏礼,焦振廉,任娟莉,等整理.北京:人民卫生出版社,2006:22.
黄庭镜.目经大成[M].汪剑,张晓琳,徐梅,校注.北京:中国中医药出版社,2015:198.
卫生部药典委员会.中华人民共和国药典:一部[S].1963年版.北京:人民卫生出版社,1964:377.
卫生部药典委员会.中华人民共和国药典:一部[S].1977年版.北京:人民卫生出版社,1978:777.
卫生部药典委员会.中华人民共和国药典:一部[S].1985年版.北京:人民卫生出版社,1985:430-431.
王淳,陈士林,宋志前,等. 经典名方药味考证及方法研究[J]. 中国实验方剂学杂志,2020,26(6):1-11.
董晓旭,刘艺,蔡梦如,等.经典名方中茯苓的本草考证[J].中国实验方剂学杂志,2021,27(12):176-181.
赵佳琛,翁倩倩,张悦,等.经典名方中术类药材的本草考证[J].中国中药杂志,2019,44(23):5248-5255.
鲁放,翟昌明,屈会化,等.白术古今炮制法小考[J].中华中医药杂志,2022,37(2):963-967.
赵佳琛,王艺涵,翁倩倩,等.经典名方中甘草的本草考证[J].中国现代中药,2020,22(8):1162-1174.
吴萍,张志国,郭爱枝,等.炙甘草历代炮制方法考证[J].中华中医药杂志,2019,34(12):5824-5828.
杜文燮.药鉴[M].张向群,校注.北京:中国中医药出版社,1993:30.
龚千锋.中药炮制学[M].4版.北京:中国中医药出版社,2016:124,154-155,243,333-334.
陈嘉谟.本草蒙筌[M].张印生,韩学杰,赵慧玲,主校.北京:中医古籍出版社,2009:50.
毕嘉谣,田湾湾,张翼,等.经典名方中山药的本草考证[J].辽宁中医药大学学报,2021,23(8):159-162.
李卫先,李福元,李达,等.药物炮制对参苓白术散健脾止泻作用的影响[J].中医学报,2015,30(5):696-699.
方谷.本草纂要[M].李明,鲍霞,校注.北京:中国中医药出版社,2015:58.
薛己.本草约言[M].臧守虎,杨天真,杜凤娟,校注.北京:中国中医药出版社,2015:89.
费伯雄.医方论[M].李铁君,点校.北京:中医古籍出版社,1987:10.
杨美权,左应梅,杨天梅,等.经典名方中白扁豆的本草考证[J].中国实验方剂学杂志,2023,29(8):116-124.
安昌,陈鸣,蔡沓栗,等.莲子的本草考证[J].中药材,2018,41(10):2457-2461.
山东省食品药品监督管理局.山东省中药饮片炮制规范[S].2012年版.济南:山东科学技术出版社,2013:145.
皇甫嵩.本草发明[M].张瑞贤,孙娟娟, 张卫,等校注.北京:学苑出版社,2011:69.
马明慧,刘秀峰,余伯阳.薏苡仁的本草考证[J].中国民族民间医药,2021,30(19):32-37.
周宇,吴孟华,罗思敏,等.薏苡仁炮制历史沿革考证[J].中国中药杂志,2020,45(11):2694-2701.
程杏轩.医述[M].王乐匋,李明回,总订校.合肥:安徽科学技术出版社,1983:1085.
桂新景,范雪花,马蕊,等.砂仁的本草考证[J].中药材,2022,45(7):1762-1768.
陈彩英,詹若挺,王小平.砂仁品种、种质资源的考证溯源[J].山东中医药大学学报,2011,35(4):354-357,376.
赵琪,王玲,吴杨璐,等. 中药桔梗的本草考证[J]. 中药材,2022,45(5):1266-1272.
邓亚羚,任洪民,叶先文,等.桔梗的炮制历史沿革、化学成分及药理作用研究进展[J].中国实验方剂学杂志,2020,26(2):190-202.
肖香龙,李信,高寒,等. 基于关键词共现的学科领域研究空白(Research Gaps)发现[J]. 情报工程,2018,4(6):37-50.
陈悦,陈超美,胡志刚,等. 引文空间分析原理与应用:CiteSpace实用指南[M]. 北京:科学出版社,2014:43.
毕奕侃,韩毅. 关键词时间分布特征视角下的研究前沿探测研究[J]. 西华大学学报(哲学社会科学版),2020,39(2):105-114.
卢广英,邢训颜,王嘉昀,等.经典名方参苓白术散的研究进展及质量标志物的预测分析[J].中国中药杂志,2022,47(19):5171-5181.
JIN W,ZHONG J,SONG Y,et al. Chinese herbal formula shen-ling-bai-zhu-san to treat chronic gastritis:clinical evidence and potential mechanisms[J]. World J Ga- stroenterol,2022,28(33):4890-4908.
陈冬平,陈晓凡,周旭,等. 参苓白术散加减辅助治疗胃癌疗效和安全性的Meta分析[J]. 中国循证医学杂志,2019,19(4):457-463.
JIANG J W,LI Z M,ZHANG F H,et al. Efficacy and safety of Shen-Ling-Bai-Zhu-San combined with chemotherapy for lung cancer:a protocol for systematic review and meta-analysis[J]. Medicine,2021,100(6):e24590.
WANG Y,LIN Z J,HUANG J,et al. An integrated study of Shenling Baizhu San against hyperuricemia:efficacy evaluation,core target identification and active component discovery[J]. J Ethnopharmacol,2022,295:115450.
ZHANG Y,LU L,LIU Y W,et al. Predicting the molecular mechanism of Shenling Baizhu San in treating convalescent patients with COVID-19 based on network pharmacology and molecular docking[J]. Nat Prod Commun,2021,16(10):1934578X2110460.
0
Views
19
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution